The big intestine is where colon cancer typically first manifests itself (colon). The digestive system ends with the colon. Colon cancer can strike anyone at any age, but it often strikes older persons. Small, benign (noncancerous) cell clusters called polyps commonly grow on the interior of the colon as the first signs of the condition. Some of these polyps may eventually develop into colon cancer.
People affected with colorectal cancer can see the symptoms such as a persistent change in bowel habits, including diarrhea or constipation or a change in the consistency of the stool, rectal bleeding or blood in the stool, persistent abdominal discomfort, such as cramps, gas or pain, a feeling that the bowel doesn't empty, weakness or fatigue, unexplained weight loss.
Due to various risk factors, colorectal cancer incidences have been rising globally, becoming a significant socio-economic issue. This is expected to act as a driver in the global colorectal cancer diagnostics market growth.
Access Full Report @ https://www.databridgemarketresearch.com/reports/europe-colorectal-cancer-diagnostics-market
Data Bridge Market Research analyzes that the Europe Colorectal Cancer Diagnostics Market is expected to reach the value of USD 1,765.81 million by 2030, at a CAGR of 7.7% during the forecast period.
Key Findings of the Study
Rise in the Number of Patients Suffering from Diverticulitis and Ulcerative Colitis
Diverticulitis refers to inflammation of the diverticula, which are small pouches that form in the colon lining. Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) where people develop inflammation and ulcers in the lining of the large intestine. Treatment options include antibiotics, a temporary, clear liquid diet, pain relief medication, and surgery to remove part of the colon for a few cases only.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 – 2020)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
Product Type (Instruments, Consumables & Accessories), Test Type (Stool Examination, Imaging Test, Biopsy, Blood Test, Tumour markers, Others), Cancer Type (Adenocarcinoma, Colorectal Lymphoma, Gastrointestinal Stromal Tumors, Carcinoid Tumors, and Others), Cancer Stages (Stage 0, Stage I, Stage II, Stage III, Stage IV), Age Group (Geriatric, Adults, and Paediatric), End User (Hospital, Diagnostic Centers, Cancer Research Centers, Ambulatory Surgical Centers, Academic Institutes, and Others)
|
|
Countries Covered
|
Germany, France, U.K, Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland and Rest of Europe
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (U.S.), Illumina Inc. (U.S.), QIAGEN (U.S.), Thermo Fisher Scientific Inc.(U.S.), Quest Diagnostics Incorporated, Inc.(U.S.), Merck KGaA.(Germany), Hologic, Inc.(U.S.), Siemens Healthcare GmbH (Germany), BD (U.S.), Myriad Genetics, Inc.(U.S.), Koninklijke Philips N.V.(Netherland), PlexBio Co, Ltd.(Taiwan), FUJIFILM Corporation (Japan), CANON MEDICAL SYSTEMS CORPORATION (Japan), FONAR Corp.(U.S.), Medonica Co. LTD (Korea), MinFound Medical Systems Co (China), Sternmed Gmbh (Germany), Bio-Rad Laboratories, Inc.(U.S.), Neusoft Corporation (China), BioFire Diagnostics (U.S.), and among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The Europe colorectal cancer diagnostics market is segmented into six notable segments such as product type, test type, cancer type, cancer stages, age group, and end user.
- On the basis of product type, the market is segmented into instruments and consumables & accessories.
In 2023, the instruments segment is expected to dominate the Europe colorectal cancer diagnostics market
In 2023, instruments segment is expected to dominate the market due to its increasing demand among the population growing with a market share of 67.16%.
- On the basis of test type, the market is segmented into stool examination, imaging test, blood test, biopsy, tumor markers, and others.
In 2023, the stool examination segment is expected to dominate the Europe colorectal cancer diagnostics market
In 2023, the stool examination segment is expected to dominate the market due to a rising prevalence of colorectal cancer due to a rising prevalence of colorectal cancer growing with a market share of 39.12%.
- On the basis of cancer type, the Europe colorectal cancer diagnostics market is segmented into adenocarcinoma, colorectal lymphoma, gastrointestinal stromal tumors, carcinoid tumors, and others. In 2023, the adenocarcinoma segment is expected to dominate the market with a market share of 61.80%.
- On the basis of cancer stages, the Europe colorectal cancer diagnostics market is segmented into stage III, stage IV, stage ii, stage I, stage 0. In 2023, stage III segment is expected to dominate the market with a market share of 41.03%.
- On the basis of age group, the Europe colorectal cancer diagnostics market is segmented into geriatric, adults, pediatric. In 2023, geriatric segment is expected to dominate the market with a market share of 46.74%.
- On the basis of end user, Europe colorectal cancer diagnostics market is segmented into hospitals, diagnostic centers, cancer research centers, ambulatory surgical centers, academic institutes, others. In 2023, hospitals segment is expected to dominate the market with a market share of 30.49%.
Major Players
Data Bridge Market Research analysis F. Hoffmann-La Roche Ltd (Switzerland), FUJIFILM Corporation (Japan), Thermo Fisher Scientific Inc. (U.S.), CANON MEDICAL SYSTEMS CORPORATION. (Japan), and Koninklijke Philips N.V. as the major market players in Europe colorectal cancer diagnostics market.
Market Development
- In December 2022, Quest Diagnostics, the world's leading provider of diagnostic information services, and Northern Light Health, a large integrated healthcare system in Maine, announced a strategic laboratory collaboration designed to broaden access to innovative, quality, and cost-effective laboratory services powering affordable care for communities in Maine.
- In November 2022, Abbott was recognized by the Consumer Technology Association (CTA) with three CES 2023 Innovation Awards for its life-changing technologies that are advancing the health tech industry and improving the lives of people worldwide. The CTA is the organization behind the Consumer Electronics Show (CES), the most influential technology event in the world.
- In October 2022, Thermo Fisher Scientific Inc. announced that it would expand its laboratory operations in Highland Heights, Kentucky, helping customers deliver life-changing medicines to patients. The current facility, which includes central lab and biomarker operations, provides biopharma customers with high-quality laboratory services to accelerate drug development.
- In June 2022, Abbott announced that it is developing a new bio wearable that will continuously monitor glucose and ketone levels in one sensor. The system has secured breakthrough device designation from the U.S. Food and Drug Administration, which is designed to expedite the review of innovative technologies that can improve the lives of people with life-threatening or irreversibly debilitating diseases or conditions.
- In April 2022, Merck, a leading science and technology company, announced several organizational changes and a new operating model to support the long-term growth strategy of the Life Science business sector and better serve its global customers' evolving needs.
Regional Analysis
Geographically, the countries covered in the Europe colorectal cancer diagnostics market report are Germany, France, U.K, Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland and Rest of Europe.
As per Data Bridge Market Research analysis:
Germany is the dominant and fastest growing country in Europe colorectal cancer diagnostics market during the forecast period 2023 - 2030
Germany dominating and fastest growing country in Europe colorectal cancer diagnostics market owing to the higher level of investments by various manufacturers and increasing demand for pharmaceutical products manufacturing in the region. Germany will continue to dominate the colorectal cancer diagnostics market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period.
For more detailed information about the Europe colorectal cancer diagnostics market report, click here – https://www.databridgemarketresearch.com/reports/europe-colorectal-cancer-diagnostics-market
